Member Info for Kaneonaim

What’s worrying is the twitter/X account is just an echo chamber of posts from this board so many times information has been posted here then shared by the company via twitter. It should be the other way round. I’m going back under my rock looking at the price here is too unbearable.

GLA!

At least Vanessa is happy. She posted this on X

I'm delighted to announce I'm a tiny equity holder and an advisor to TMC2, a groundbreaking AI VC and incubator, whose team I have known for years. Their approach has revolutionized investment protection in AI and impacted business in the UK. Read it here

https://x.com/vanessaneumann/status/1801151229440983363

These people just don’t live in the real world!!

Https://caseboard.io/cases/541f905d-03a9-43f5-bce2-08dde742e3ba

https://caseboard.io/cases/6957f707-aea5-4081-8990-1eb6a6e36b34

From what I’ve read in these 2 cases they had 2 claims brought against them one by Fintech Leaders Fund LLC and the other Cogut Craig,Cogut Deborah,Cogut Family Partnership VII.

Https://x.com/IQAI_IB/status/1801654631870677003

Excellent expert discussion about the advantages of DSC perfusion imaging for brain tumors (diagnosis, grading, guiding biopsy, treatment planning, follow-up, etc)! Features exclusive to IB Software (IB Neuro) were highlighted!

@Applied_Rad

@TheASNR

AJNR Scantastic - Dr. Lea Alhilali creatively takes the confusion out of tumor perfusion.

https://www.youtube.com/watch?v=aFZvO6PeWeA

The objective of this program is to provide GaM for compassionate use in patients with relapsed/refractory histologic or molecular glioblastoma who have exhausted available treatments.

The population of this program is adult patients aged greater than or equal to 18 years with a diagnosis of relapsed/refractory histologic or molecular glioblastoma, according to the WHO 2021 diagnostic criteria.

Molecular glioblastoma is characterized as an IDH-wildtype diffuse and astrocytic glioma in adults if there is microvascular proliferation or necrosis or TERT promoter mutation or EGFR gene amplification or +7/-10 chromosome copy number changes

Full description

This is an intermediate-sized expanded access treatment protocol. GaM (GaM) will be provided as 500 mg capsules and will be self-administered once daily by mouth at the assigned dose level on a 28-day cycle (one cycle is 28 days). Initially, the patients will be provided a three (3) cycle prescription (a 28-day supply with two refills); enough total supply of GaM for three full cycles to allow for self-administration at home. It should be taken on an empty stomach. After that initial period, subsequent GaM will be provided to patients for continued self-administration.

At the treating physician's discretion, additional medication(s) may be administered. Clinical use of cancer-supportive care therapies is unrestricted, but the non-emergent use of additional anti-cancer therapies requires prior consultation with xCures and Imaging Biometrics. xCures along with Imaging Biometrics will be consulted prior to the non-emergent administration of any additional anti-cancer medications. xCures, along with Imaging Biometrics, should be consulted prior to any schedule modifications or the addition of other therapy. The patients may discontinue therapy at any time for any reason. The treating physician can discontinue therapy with GaM at any time for any reason.

https://ctv.veeva.com/study/expanded-access-to-gallium-maltolate-gam

https://clinicaltrials.gov/study/NCT06404034?tab=history&a=1#version-content-panel

Primary Outcome Measures :

1. Maximum-tolerated dose. [ Time Frame: Each 28-day cohort ]This will be determined from the incidence of dose limiting toxicities at each dosage.


From half year report August 2023

The amendment will expand the targeted enrolment from 24 to 36 subjects and allow for continued dose escalation. The MTD determined in Phase 1 will define the "recommended phase II dose" (RP2D) that will be used in the Phase 2 trial. This amendment is the fastest and most efficient way to satisfy the primary goal of the Phase 1.

 

Given the expanded target enrolment and assuming the strong momentum in patient enrolment continues, it is anticipated that Phase 1 will close in 2024. After enrolment closes, the last patients enrolled will remain on the trial until all required study data is collected. Analysing the data and documenting the phase 1 results is expected to be completed in the second half of 2024.

 

While the MTD is being determined in the final stages of Phase 1, the clinical team will complete the Phase 2 protocol. The Phase 2 trial is designed to evaluate preliminary evidence of efficacy. Ideally, the Phase II trial will open for patient recruitment in early 2025. This will be a multi-centre trial with a tentative target enrolment of approximately 65 patients over a three-year duration. The design of the Phase 2 study is currently being defined. Factors such as the Phase 1 results and whether the study will be a comparison to historical controls or if it will be randomized (comparing patients with standard treatment alone against those receiving standard treatment with GaM) will influence the overall scope and cost.

 The multi-site Phase 2 trial will require new funding which we anticipate will come substantially from a partnership arrangement with a large pharmaceutical company and grants, including those from charitable foundations and other institutions. We anticipate publishing frequent updates to our shareholders as developments unfold.

From 13 October 2023

 letter to shareholders

Our sponsored phase 1 clinical trial of oral gallium maltolate (GaM) has increased momentum since it opened in March of 2022. Patients enrolled and were prescribed escalating doses of the agent per the trial's design with the primary goal of identifying the maximum tolerated dose (MTD) for a phase 2 trial. Because patients have tolerated the agent so well, an amendment to the trial's IND had to be written and has since been approved to allow subjects to be administered higher dose levels. This is because the patients have tolerated the initial doses of the agent extremely well and a phase 2 trial requires that a MTD be determined. This dose escalation corresponds to an increase of subjects from 24 to 36. As soon as the MTD is determined, enrollment for the phase 1 trial will halt, data will be summarised, and focus will shift for the commencement of the phase 2 trial.

In recent months I have received several requests for information on gallium maltolate in the treatment of glioblastoma and so with the help of a volunteer, Mario Iannaccone who took an interest and studied the topic in depth, I decided to write this article.

We all know that glioblastoma multiforme (GBM) is known for its poor prognosis and poor long-term survival. In recent decades, progress in treatment has been limited, with the Stupp protocol, which combines surgery, temozolomide (TMZ) and radiotherapy, remaining the standard of care. However, a new frontier in research may offer unexpected hope: gallium maltolate.

Gallium maltolate is a promising compound in the treatment of glioblastoma. Wisconsin College of Medicine professor Jennifer Connelly has led numerous studies, indicating the potential of this compound in the treatment of GBM. But why gallium? Gallium, similar to iron in the periodic table, can “trick” tumor cells that require iron to grow, entering the cells through transferrin receptors and disrupting vital tumor processes.

Preclinical studies have shown that gallium maltolate taken orally effectively inhibits the growth of glioblastoma by targeting iron metabolism in tumor cells. Experiments on tumor cells and animal models have shown that gallium maltolate can significantly reduce the growth of GBM. In preclinical studies, glioblastoma cells treated with gallium showed a reduction in tumor volume and growth rate.

In 2022, the first phase 1 clinical trial of gallium maltolate for recurrent glioblastoma was launched. Preliminary results have been encouraging, showing not only good tolerability of the drug but also potential efficacy in reducing tumor size. In addition, the Food and Drug Administration (FDA) recently granted orphan drug designation to gallium maltolate for the treatment of relapsed and refractory glioblastoma.

https://www.glioblastomamultiforme.it/en/gallium-maltolate-a-new-hope-in-the-treatment-of-glioblastoma/

It’s just further validation he couldn’t give 2 shets about regular personal investors.

Tb probably sulking as he’s not been reappointed hopefully we see the mother of rally’s off the back of it.

Is a troll from feedback plc obviously bitter that Trevor their ex director has developed a better app than their app bleepa lol!! And for less than half the cost!!

LIMITATION OF LIABILITY

Under no circumstances, including, without limitation, negligence, shall IB or its parents, subsidiaries, affiliates, officers, directors, employees, agents, or suppliers be liable for any direct, indirect, incidental, special or consequential damages arising from or in connection with the use of or the inability to use this Site or any content contained on the Site, or, except as otherwise provided under applicable laws and regulations regarding the security of personal data, resulting from unauthorized access to or alteration of your transmissions or data, or other information that is sent or received or not sent or received.

INDEMNIFICATION

You agree to indemnify, defend, and hold IB and IB’s affiliates, business partners, officers, directors, employees, and agents harmless from any loss, liability, claim, action, suit, demand, damage, or expense (including reasonable legal fees, costs of investigation and court costs) asserted by any third party relating in any way to, or in respect of, your use of the Site, any third party applications, software, or content you post or share on or through the Site, or breach of these Terms of Use. IB reserves the right to assume the exclusive defense and control of any matter subject to indemnification by you, which shall not excuse your indemnity obligations.

LINKS AND THIRD PARTY CONTENT

The Site also provides links to other sites, such as professional organizations and sales partners. While we try to link only to sites that share our high standards, the content and privacy standards of these other sites is beyond our control. These sites and their related content may set third party cookies over which we do not have access or control. The use of cookies by third parties is not covered by our Privacy Policy.

DISCLAIMER

This Site and the Content available through it are provided on an “as is” and “as available” basis.

To the fullest extent permissible pursuant to applicable law, IB and its affiliates disclaim all warranties of any kind, whether express or implied, including without limitation any warranty of merchantability, fitness for a particular purpose or non-infringement.

You expressly agree that any use of this site, including all content, data or software distributed by, downloaded or accessed from or through the site, is at your sole risk. You understand and agree that you will be solely responsible for any damage to your business, your computer system or loss of data that results from the download of such content, data and/or software.

IB does not make any warranty that this Site or its Content will meet your requirements, or that this Site or its Content will be uninterrupted, timely, secure, or error free, or that defects, if any, will be corrected, nor does IB make any warranty as to the results that may be obtained from use of this Site or its Content or as to the accuracy, completeness or reliability of any information obtained through use of this Site. Except as otherwise provided under applicable laws and regulations regarding the security of personal data, IB disclaims any warranty or representation that confidentiality of information transmitted through the site will be maintained.

No advice or information, whether oral or written, obtained by you from IB or third parties through the site shall create any warranty. Some jurisdictions do not allow the limitation or exclusion of certain warranties or conditions, so some of the above exclusions may not apply to you.

All content on this Site, including but not limited to design, text, software, technical drawings, configurations, graphics, other files, and their selection and arrangement (“Content”), are either the property of IB. All rights reserved.

The Contents of the Site may not be modified, copied, distributed, framed, reproduced, republished, downloaded, displayed, posted, transmitted, or sold in any form or by any means, in whole or in part, without IB’s prior written permission, except that you may download and print content for uses that are not competitive with or derogatory to IB, provided that you keep all copyright or other proprietary notices intact.

TRADEMARKS

All trademarks on the Site are either trademarks or registered trademarks of IB or its affiliates or licensors and may not be copied, imitated, or used, in whole or in part, without the prior written permission of IB. All page headers, custom graphics, icons, and scripts are service marks, trademarks and/or trade dress of IB, and may not be copied, imitated, or used, in whole or in part, without the prior written permission of IB. Other trademarks, registered trademarks, product names, and company names or logos displayed on the Site are the property of their respective owners.

PATENTS

IB’s products and processes are covered by patents and are subject to other trade secret and proprietary rights. IB reserves all such rights. No transfer or grant of rights under any patents is made or is to be implied by any provision of these Terms of Use. You agree not to infringe upon such rights or decompile, reverse engineer, or disassemble any of IB’s products or processes.

PRIVACY PROTECTION

You acknowledge and agree that IB may use the data collected in the course of our relationship for the purposes identified in our Privacy Protection.

Content, Product and Service Information – Limitations

All content available through the Site, including but not limited to data, technical drawings, configurations, quote and order information, and catalog listings is believed to be accurate. However, you should independently evaluate the accuracy of the information and the usefulness for your particular needs of any content, product or service available through the Site. Specifications for products and services are subject to change without notice, and IB reserves the right to make changes without notice to processing, materials, or configuration. All information on the Site is subject to the below disclaimer section.

POLICIES

Imaging Biometrics, LLC, an IQ-AI company, shares your concerns regarding internet privacy. We think you should know how we treat the information that we receive from you, and have created this statement of our policy to demonstrate our continued commitment to privacy.

IQ-AI, Ltd is registered in Jersey 2044 with offices at P. O. Box 264, Forum 4, Grenville Street, St Helier, Jersey Channel Islands, JE4 8TQ.

PRIVACY PROTECTION POLICY

Personal Data Collection and Use
Imaging Biometrics (IB) does not require users to disclose personal information, such as name, address, e-mail address and occupation. However, in order to obtain specific information, documents, or trials of our software, you may have to register and provide certain personal data. IB hereby informs you that all such personal data you may provide online are intended for use solely by IB to further discuss client/partner interest in our products and services. Such data shall not be disclosed to third parties other than third parties hired by IB to host or manage the Site. Third parties are required to maintain the confidentiality of said data and are prohibited from using the data for any purpose other than the operation or management of the Site. IB agrees to take all such reasonable measures as may be available to it in order to ensure the confidentiality of said personal data. You have the right to oppose, access and correct such personal data. You may exercise this right at any time by sending a request in writing to:

Imaging Biometrics, LLC
13416 Watertown Plank Road, Ste #260

Elm Grove, WI 53122 USA

info@imagingbiometrics.com.

Any related changes or deletions will be made as soon as reasonably practicable and in any event, no later than five working days following receipt of your notice.

INFORMATION IB DOES NOT COLLECT

IB does not intentionally collect sensitive personal information, such as social security numbers, ethnicity, genetic data, health information, or religious affiliation.

TERMS OF USE

These Terms of User (Terms) may be changed from time to time and without further notice. Your continued use of the Site after any such changes constitutes your acceptance of the new terms. If you do not agree to abide by these or any future terms, please do not use the Site or download materials from it.

IB may terminate, change, suspend or discontinue any aspect of the Site, including the availability of any features, at any time. IB may remove, modify or otherwise change any content, including that of third parties, on or from this Site. IB may impose limits on certain features and services or restrict your access to parts or all of the Site without notice or liability. IB may terminate your use of the Site at any time in its sole discretion.

Copyrights

All content on this Site, including but not limited to design, text, software, technical drawings, configurations, graphics, other files, and their selection and arrangement (“Conten

Yes I got a reply this morning to a question asked.

Fantastic to connect with clinicians at #ASNR2024 who are interested in taking the "confusion out of DSC perfusion". Visit

@IQAI_IB

at booth 215 to learn about quantitative #FTB maps, our handheld app #IBNimble for the management of brain mets, and more!

@TheASNR

Another group (Siakallis, et al) presented at ASNR in Las Vegas showed that choosing IB Neuro’s standardized and leakage corrected rCBV is best when developing AI algorithms to identify molecular marker status

Excellent news this morning!!

Something else they’ve failed to update shareholders on. Or I missed this?

xCures facilitates Expanded Access to GaM

xCures and Imaging Biometrics are collaborating on an Expanded Access Protocol (EAP) providing compassionate use of gallium maltolate for participants with relapsed/refractory histologic or molecular glioblastoma who have exhausted standard-of-care therapies. Additional information can be found at the links below.

Oral GaM – Musella Foundation (short video)

Oral GaM – Musella Foundation (long version)

Clinicaltrials.gov (NCT06404034)

If you or your doctor believes you, or someone for whom you are their Legally Authorized Representative, may be eligible to enroll, please register here. Registration takes about 5 minutes to complete.

Once your registration is complete, the xCures team will coordinate enrollment in the EAP and/or offer alternative treatment assistance as appropriate. We will work directly with your treating team to ensure the proper regulatory work has been completed and the order for gallium maltolate has been processed.

Please note that this program has costs. Once your registration is complete, please contact Linda Herman at eap@imagingbiometrics.com or by phone at 262-439-8252 for information on payment next steps and inquiries regarding financial assistance for this EAP.

Please feel free to contact the xCures team at expandedaccess@xcures.com with any questions about this process.

https://xcures.com/

Launched in 2018, xCures is a paradigm shift in enabling healthcare data to impact successful patient outcomes.

In its early days, the company focused on a major challenge in healthcare: managing and navigating the complexities of large-scale cancer patient data and fragmented access to medical records.

In 2021, xCures introduced AI-assisted portals to provide users rapid and comprehensive access to critical data and actionable insights – a pivotal advancement in the xCures story.

Moving into 2024, xCures is expanding its horizons beyond cancer to include all conditions and making the xCures Platform available to anyone. This will further broaden the impact and provide significant new capabilities for overall patient care and research.

Our Vision

To transform the value of US healthcare data by delivering real-time, regulatory-grade data to improve care, drive innovation, and accelerate the development of new treatments.